Previous 10 | Next 10 |
CytoDyn Submits Requested Datasets to FDA for Biologics License Application VANCOUVER, Washington, May 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 14...
VANCOUVER, Washington, May 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced ...
As the worldwide death toll surpasses 250K, scientists from around the world are in a race to discover and test effective therapeutics to treat COVID-19. Researchers are either attempting to try an already approved drug used in another indication, test a pipeline candidate or discover a novel ...
VANCOUVER, Washington, May 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, tod...
The law firm of Federman & Sherwood has initiated an investigation into CytoDyn Inc. (OTC: CYDY) and its officers and directors, with respect to possible violations of federal securities laws. On April 27, 2020, CytoDyn, a late-stage biotechnology company, issued a press release indicatin...
VANCOUVER, Washington and WINSTON-SALEM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic...
This article reviews CytoDyn's ( OTCQB:CYDY ) 5/1/2020 Next Superstock Live 58 minute promo youtube , [the YouTube] particularly as it relates to CytoDyn's evaluation of leronlimab's MOA. I will also discuss CEO Nader Pourhassan's [NP] recent stock trade which seems to have drawn such outsize...
Manuscript Posted Online to Research Square and MedRxiv Pre-print Server VANCOUVER, Washington, May 05, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting leaders presenting at it’s NEXT SUPER STOCK investor livestream conference series that are making news this week. fuboTV (OTC: FUBO) Appoints Edgar Bron...
CytoDyn ( OTCQB:CYDY -8.8% ) is under early pressure on the heels of a report from STAT's Adam Feuerstein questioning management's motives behind its aggressive promotion of leronlimab for the treatment of COVID-19 patients. More news on: CytoDyn Inc., Healthcare stocks news, Stocks on...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...